| Literature DB >> 35842978 |
C I Sartorao Filho1, C I Sartorao Neto2, A L V Sartorao3, D C Terribile3, R Mello4, B B Mello3, M C Zoqui3, D O Duarte3, L E G Cachoni3, V C Q Bisseto3, E A C Ribeiro3.
Abstract
BACKGROUND: Limited research has examined mobile phone-based platforms for survey recruitment, especially during the COVID-19 pandemic in Brazil. Our objective was to investigate the feasibility and representativeness of mobile phone-based advertisement during a preliminary study about COVID-19 vaccine hesitation in Brazil. Moreover, we evaluate whether the older population can be reached through mobile phone-based platforms of the survey.Entities:
Keywords: COVID-19; Cell phone; Demography; Survey and questionnaires; Vaccination hesitancy
Mesh:
Substances:
Year: 2022 PMID: 35842978 PMCID: PMC9278996 DOI: 10.1016/j.ijmedinf.2022.104832
Source DB: PubMed Journal: Int J Med Inform ISSN: 1386-5056 Impact factor: 4.730
Respondents Characteristics (N = 355).
| Mean (SD) | 33.98 (14.99) |
| Range | 18–88 |
| 18–29 | 179 (50.4) |
| 30–44 | 96 (27.0) |
| 45–59 | 53 (14.9) |
| ≥60 | 27 (7.6) |
| Female | 153 (43.1) |
| Male | 202 (56.9) |
| College graduate or above | 80 (22.5) |
| Yes (confirmed or clinically suspected) | 37 (10.4) |
| Fair/poor | 56 (15.8) |
| Coronavac | 81 (22.8) |
| Pfizer | 176 (49.6) |
| Astrazeneca | 98 (27.6) |
| Definitively or probably will take | 286 (80.6) |
| Not sure | 44 (12.4) |
| Probably or definitively will not take | 25 (7.0) |
*Unless otherwise indicated, data are the respondents' number and percentage ().
Percentages may not total 100 owing to rounding.
The population and respondents group comparison according to Chi-squared goodness of fit calculation.
| Characteristics | Population | % | Respondents | % | Qui square | |
|---|---|---|---|---|---|---|
| N = 4667 | N = 355 | |||||
| Female | 1935 | 41.5 | 153 | 43.1 | ||
| Male | 2732 | 58.5 | 202 | 56.9 | 0.364 | 0.546 |
| 18–29 years | 2070 | 44.4 | 179.0 | 50.4 | 1.808 | 0.178 |
| 30–44 years | 1538 | 33.0 | 96 | 27.0 | 2.781 | 0.095 |
| 45–59 years | 760 | 16.3 | 53 | 14.9 | 0.325 | 0.568 |
| ≥ 60 years | 299 | 6.4 | 27 | 7.6 | 0.679 | 0.409 |
| Morbidities | 512 | 11.0 | 56 | 15.8 | 5.832 | 0.157 |
| Coronavac | 908 | 19.5 | 81 | 22.8 | ||
| AstraZeneca | 2075 | 44.5 | 98 | 27.6 | 13.245 | 0.001 |
| Pfizer | 1684 | 36.1 | 176 | 49.5 | ||
The percentages may not total 100 owing to rounding.
P-value < 0.05.
Comparison between Population and respondent age groups.
Welch's test for the comparison between population and respondent age groups.
| Respondents N = 355 | Population N = 4667 | |
|---|---|---|
| 33.97 | 35.05 | |
| 14.99 | 14.19 | |
| Welch's | ||
| −1.3059 | ||
| 403.7489 | ||
| 0.1923 | ||
P-value < 0.05.